PetVivo Inc. (PETV)
0.53
-0.06 (-10.77%)
At close: Mar 31, 2025, 10:07 AM
Company Description
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals.
Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.
The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications.
PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
PetVivo Inc.

Country | United States |
IPO Date | Sep 8, 2014 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 20 |
CEO | John Lai |
Contact Details
Address: 5251 Edina Industrial Boulevard Minneapolis, Minnesota United States | |
Website | https://www.petvivo.com |
Stock Details
Ticker Symbol | PETV |
Exchange | NASDAQ |
Fiscal Year | April - March |
Reporting Currency | USD |
CIK Code | 0001512922 |
CUSIP Number | 716817408 |
ISIN Number | US7168174081 |
Employer ID | 99-0363559 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
John Lai | Chief Executive Officer, President & Director |
Garry N. Lowenthal | Chief Financial Officer |
April Boyce | Vice President of Sales & Marketing |
Gary DeMel | Executive Vice President of Business Development |
John F. Dolan | General Counsel, Chief Business Development Officer & Secretary |
Michael Eldred BA, MBA | Commercialization & Operations Advisor and Executive Director |
Randy Wenthold | Chief Science Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2025 | 8-K | Current Report |
Mar 10, 2025 | 8-K | Current Report |
Feb 28, 2025 | 8-K | Current Report |
Feb 18, 2025 | 8-K | Current Report |
Feb 18, 2025 | 8-K | Current Report |
Feb 14, 2025 | 10-Q | Quarterly Report |
Feb 13, 2025 | 8-K | Current Report |
Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 11, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 04, 2025 | 8-K | Current Report |